Skip to main content

Table 1 Patient baseline characteristics, surgical overview, and status at final follow-up (n = 20)

From: Percutaneous autologous impaction bone graft for advanced femoral head osteonecrosis: a retrospective observational study of unsatisfactory short-term outcomes

Case

Age (years)/sex

Background factors for ONFH (disease)

Side

Baseline stage/type

Opposite side stage/type

Surgery time (min)/blood loss (g)

Stage/type at recent follow-up

Follow-up period (months)

1

24/F

Steroid use (MCTD)

R

Stage 3A/type C2

Healthy

122/80

Stage 3A/type C2

42

2

53/F

Steroid use (dermatomyositis)

R

Stage 3A/type C2

rhFGF-2 therapya

Stage 1/type C2

96/35

THA

42

3

41/M

Alcohol intake

R

Stage 3A/type C2

Healthy

60/180

THA

42

4

33/M

Idiopathic

R

Stage 3B/type C2

Healthy

50/10

Stage 3B/type C2

40

5

29/F

Steroid use (Alopecia areata)

L

rhFGF-2 therapya Stage 3A/type C2

THAb

67/10

Stage 4/type C2

40

6

18/F

Steroid use (ALL)

R

Stage 3B/type C2

Stage 3A/type C2

48/60

Stage 3B/type C2

39

7

56/M

Steroid use (IP) + alcohol intake

R

Stage 3A/type C2

THAb

50/350c

Stage 3B/type C2

38

8

43/M

Steroid use (EG)

R

Stage 3A/type C2

rhFGF-2 therapya

Stage 1/type C2

42/10

THA

38

9

41/M

Steroid use (EPGA)

L

Stage 3A/type C2

Healthy

67/10

THA

37

10

36/F

Steroid use (MS)

L

Stage 3A/type C1

Healthy

39/10

THA

37

11

43/M

Alcohol intake

R

Stage 3A/type C2

Healthy

46/10

Stage 3A/type C2

36

12

49/M

Steroid use (IP) + Alcohol intake

L

Stage 3A/type C2

Healthy

38/10

Stage 3B/type C2

36

13

45/M

Steroid use (nephrotic synd.)

R

Stage 3A/type C2

rhFGF-2 therapya

Stage 3A/type C2

60/10

Stage 3A/type C2

34

14

27/F

Steroid use (SLE)

R

Stage 3A/type C2

Healthy

40/10

Stage 3B/type C2

34

15

45/M

Steroid use (SS, IP)

R

Stage 3A/type C2

Healthy

38/10

Stage 3A/type C2

33

16

44/M

Steroid use (Bullous)

R

Stage 2/type C1

Bone grafting

Stage 2/type C1

50/10

Stage 2/type C1

33

17

44/F

Alcohol intake

R

Stage 3A/type C2

THA

62/10

Stage 3B/type C2

32

18

36/M

Alcohol intake

R

Stage 3A/type C2

Healthy

30/10

Stage 3A/type C2

32

19

44/M

Alcohol intake

L

Stage 3A/type C2

Stage 1/type C2

47/10

THA

31

20

70/F

Steroid use (nephrotic synd.)

L

Stage 3A/type C2

Stage 2/type C1

39/10

THA

29

 

Mean ± SD, 41±11; median (range), 43 (18–70); M:F=12:8

Steroid use, 12; alcohol intake, 5; idiopathic, 1; steroid use + alcohol use, 2

R, 12; L, 8

Stage 2 = 1; stage 3A = 17; stage 3B = 2/type C1, 2; type C2, 18

THA = 3; healthy = 10; stage 1 = 3; stage 2 = 2; stage 3A = 2/type C1, 2; type C2, 5

Mean ± SD 54±21/42±83; median (range), 49 (30–122)/10 (10–350)

THA = 7; stage 2 = 1; stage 3A = 5; stage 3B = 6; stage 4 = 1/type C1, 1; type C2, 12

Mean ± SD 36±3; median (range), 36.5 (29–42)

  1. Type A had the smallest osteonecrosis, while type C2 had the largest osteonecrosis extended laterally to the acetabular edge. Stage 3A: femoral head collapse within 3 mm. Underline: detected radiological progression (radiological progressive change classified by the Japanese investigation committee classification). Underline: the operated side
  2. M male, F female, SD standard deviation, ONFH osteonecrosis of the femoral head, MCTD mixed connective tissue disease, ALL acute lymphocytic leukemia, IP interstitial pneumonia, EG eosinophilic gastroenteritis, EPGA eosinophilic granulomatosis with polyangiitis, MS multiple sclerosis, synd syndrome, SLE systemic lupus erythematosus, SS Sjögren’s syndrome, R right, L left, rhFGF recombinant human fibroblast growth factor, THA total hip arthroplasty
  3. aClinical trial of rhFGF-2 regenerative therapy was previously performed in our hospital
  4. bBoth ONFH sides were operated simultaneously. THA was performed first, followed by bone grafting on the opposite side using the collapsed femoral head removed during THA
  5. cThe total volume loss including THA on the opposite side
Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X